Publicado
Study of the antifungal activity of ibuprofen and its association with amphotericin B or ketoconazole against Candida spp.
Estudio de la actividad antifúngica del ibuprofeno y su asociación con anfotericina B o ketoconazol contra Candida spp.
Estudo da atividade antifúngica do ibuprofeno e sua associação com anfotericina B ou cetoconazol contra Candida spp.
DOI:
https://doi.org/10.15446/rcciquifa.v49n2.89516Palavras-chave:
Candida, ibuprofen, antifungals, association (en)Candida, ibuprofeno, antifúngicos, associação (pt)
Candida, ibuprofeno, antifúngicos, asociación (es)
Downloads
The objective was evaluating the antifungal activity of ibuprofen alone and when associated with amphotericin B or ketoconazole against Candida species. Strains of C. albicans, C. tropicalis, C. guilliermondii, C. krusei and C. parapsilosis were used. The minimum inhibitory concentration (MIC) was determined by the microdilution method and the association study performed through the checkerboard assay. The concentration of 512 µg/mL inhibited approximately 65% of the tested strains, while against 35% of the strains presented MIC values above 2048 µg/mL. Associations of ibuprofen with amphotericin B against C. tropicalis and ibuprofen with ketoconazole against C. krusei showed synergistic effect. Antagonistic effects were evidenced in the combination of ibuprofen with amphotericin B against C. guilliermondii and C. albicans, as well as in the association of ibuprofen with ketoconazole against C. albicans and C. tropicalis. Through the experiments, it was found that ibuprofen showed antifungal activity against most of the Candida species tested. The combinations of ibuprofen and antifungals had synergistic effects. However, antagonistic results were evidenced in the association with ibuprofen, which would make clinical applicability difficult. Therefore, studies of this combined activity should be investigated, considering that this association may be positive for antifungal therapy.
El objetivo fue evaluar la actividad antifúngica del ibuprofeno solo y asociado con anfotericina B o ketoconazol contra especies de Candida. Se utilizaron cepas de C. albicans, C. tropicalis, C. guilliermondii, C. krusei y C. parapsilosis. La concentración inhibitoria mínima (MIC) se determinó mediante el método de microdilución y el estudio de asociación fue realizado a través del ensayo de checkboard. La concentración de 512 µg/mL inhibió aproximadamente el 65% de las cepas analizadas, mientras 35% de las cepas presentaron valores de MIC superiores a 2048 µg/mL. Las asociaciones de ibuprofeno con anfotericina B contra C. tropicalis e ibuprofeno con ketoconazol contra C. krusei mostraron un efecto sinérgico. Se evidenciaron efectos antagonistas en la combinación de ibuprofeno con anfotericina B contra C. guilliermondii y C. albicans, así como en la asociación de ibuprofeno con ketoconazol contra C. albicans y C. tropicalis. Se descubrió, a través de los experimentos, que el ibuprofeno mostró actividad antifúngica contra la mayoría de las especies de Candida probadas. Las combinaciones de ibuprofeno y antifúngicos tuvieron efectos sinérgicos. Sin embargo, se evidenciaron resultados antagónicos en la asociación con ibuprofeno, lo que dificultaría la aplicabilidad clínica. Por lo tanto, los estudios de esta actividad combinada deben investigarse, considerando que esta asociación puede ser positiva para la terapia antimicótica.
O objetivo do estudo foi avaliar a atividade antifúngica do ibuprofeno sozinho e quando associado com anfotericina B ou cetoconazol contra espécies de Candida. Foram utilizadas cepas fúngicas de C. albicans, C. tropicalis, C. guilliermondii, C. krusei e C. parapsilosis, entre isolados clínicos e cepas padrão. A concentração inibitória mínima (CIM) foi determinada pela técnica de microdiluição e o estudo de associação realizado através do ensaio checkerboard. A concentração de 512 µg/mL foi capaz de inibir, aproximadamente, 65% das cepas ensaiadas, enquanto que 35% das estirpes apresentaram valores da CIM acima de 2048 µg/mL. Associações do ibuprofeno com anfotericina B contra C. tropicalis e ibuprofeno mais cetoconazol contra C. krusei mostraram efeito sinérgico. Efeitos antagônicos foram evidenciados na combinação do ibuprofeno com anfotericina B contra C. guilliermondii e C. albicans, como também na associação do ibuprofeno com cetoconazol contra C. albicans e C. tropicalis. Por meio dos experimentos, pôde-se afirmar que o ibuprofeno exerceu atividade antifúngica contra a maioria das espécies de Candida ensaiadas. Os efeitos das combinações entre o ibuprofeno e os antifúngicos promoveram efeitos sinérgicos. No entanto, resultados antagônicos foram evidenciados na associação com o ibuprofeno, o que dificultaria aplicabilidade clínica. Logo, estudos dessa atividade combinada devem ser investigados, pois esta associação pode traçar pontos positivos na terapia antifúngica.
Referências
A. Mehta, S.V. Date, Determination of incidence of different Candida spp. in clinical specimens and characterisation of Candida species isolates, Indian J. Microbiol. Res., 23(4), 342-351 (2016).
G.D. Brown, D.W. Denning, S.M. Vevitz, Tackling human fungal infections, Science, 336(6082), 647 (2012).
O. Gudlaugsson, S. Gillespie, K. Lee, V.J. Berg, J. Hu, S. Messer, et al., Attributable mortality of nosocomial candidemia revisited, Clin. Infect. Dis., 37(9), 1172-1177 (2003).
M. Pfaller, D. Neofytos, D. Diekema, N. Azie, H.U. Meier-Kriesche, S.P. Quan, et al., Epidemiology and outcomes of candidemia in 3648 patients: data from the prospective antifungal therapy (PATH Alliance®) registry, 2004–2008, Diagn. Microbiol. Infect. Dis., 74(4), 323-331 (2012).
S. Sharifynia, H. Badali, M.S. Sorkherizi, M.R. Shidfar, A. Hadian, S. Shahrokhi, et al., In vitro antifungal susceptibility profiles of Candida albicans complex isolated from patients with respiratory infections, Acta Med. Iran., 54(6), 376-381 (2016).
S. Silva, M. Negri, M. Henriques, R. Oliveira, D.W. Williams, J. Azeredo, Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance, FEMS Microbiol. Ver., 36(2), 288-305 (2012).
S.B. Paula, T.F. Bartelli, V. Di Raimo, J.P. Santos, A.T. Morey, M.A. Bosini, et al., Effect of eugenol on cell surface hydrophobicity, adhesion, and biofilm of Candida tropicalis and Candida dubliniensis isolated from oral cavity of HIV-infected patients, Evid. Based Complement. Alternat. Med., 2014, ID 505204 (2014).
P.T. Venturini, L. Rossato, F. Chassot, T.J. Keller, B.F. Piasentin, M.J. Santurio, et al., In vitro synergistic combinations os pentamidine, polymyxin B, tigecycline and tobramycin with antifungal agents against Fusarium spp, J. Med. Microbiol., 65(8), 770-774 (2016).
S. Yang, Y. Liao, L. Cong, X. Lu, R. Yang, In vitro interactions between non-steroidal anti-inflammatiry drugs and antifungal agents against planktonic and biofilm forms of Trichosporon asahii, PLoS One, 11(6), e0157047 (2016).
L.Y.S. Holbrook, A. Garzan, K.E, Dennis, K.S. Shrestha, S. Garneau-Tsodikova, Repurposing antipsychotic drugs into antifungal agents: Synergistic combinations of azoles and bromperidol derivatives in the treatment of various fungal infections, Eur. J. Med. Chem., 139, 12-21 (2017).
L. Gao, X. Ding, Q. Liu, Q. Wu, T. Zeng, Y. Sun, In vitro interactions between target of rampamycin kinase inhibitor and antifungal agents against Aspergillus species, Antimicrob. Agents Chemother., 60(6), 3813-3816 (2016).
L. Gao, Y. Sun. in vitro interactions of antifungal agents and tacrolimus against Aspergillus biofilms. Antimicrob Agents Chemother, 59, 11, (2015).
E. Rusu, I. Sarbu, D. Pelinescu, I. Nedelcu, T. Vassu, C. Cristescu, et al., Influence of associating nonsteroidal anti-inflammatory drugs with antifungal compounds on viability of some Candida strains, Romanian J. Infec. Dis., 17, 2 (2014).
S. Costa-de-Oliveira, M.I Miranda, A. Silva-Dias, P.A Silva, G.A Rodrigues, C. Pina-Vaz, Ibuprofen potentiates the in vivo antifungal activity of fluconazole against Candida albicans murine infection, Antimicrob. Agents Chemother., 59(7), 4289–4292 (2015).
C. Pina-Vaz, F. Sansonetti, A.G. Rodrigues, J. Martinez-de-Oliveira, A.F. Fonseca, P.A. Mardh, Antifungal activity of ibuprofen alone and in combination with fluconazole against Candida species, J. Med. Microbiol., 49(9), 831-840 (2000).
A.O. Ogundeji, H.C. Pohl, M.O. Sebolal, Repurposing of aspirin and ibuprofen as candidate anti-Cryptococcus drugs. Antimicrob. Agents Chemother., 60(8), 4799-808 (2016).
L. Cleeland, E. Squires, Evaluation of new antimicrobials in vitro and experimental animal infections, in: Antibiotics in laboratory medicine, 3rd ed., edited by: Y. Lorian, Williams & Wilkins, Baltimore, 1991, p. 739-788.
F. Hadacek, H. Greger, Testing of antifungal natural products: methodologies, comparability of results and assay choice, Phytochem. Anal., 11(3), 137-147 (2000).
National Committee for Clinical Laboratory Standards, Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard, 2nd ed., NCCLS, Wayne, 2008, p. 29.
J.N. Eloff, A sensitive and quick microplate method to determine the minimal inhibitory concentration of plant extracts for bacteria, Planta Med., 64(8), 711-713 (1998).
E.V. Costa, S.D. Teixeira, F.A Marques, M.C.T Duarte, C. Delarmelina, M.L.B. Pinheiro, et al., Chemical composition and antimicrobial activity of the essential oils of the Amazon Guatteriopsis species, Phytochemistry, 69(9), 1895-1899 (2008).
R.L. White, D.S. Burgess, M. Mandruru, J.A. Bosso, Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard and E-test, Antimicrob. Agents Chemother., 40(8), 1914–1918 (1996).
R.E. Lewis, D.J. Diekema, A.S. Messer, M.A. Pfaller, M.E. Klepser, Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species, J. Antimicrob. Chemother., 49, 345–351 (2002).
J. Correa-Royero, V. Tangarife, C. Durán, E. Stashenko, A. Mesa-Arango, In vitro antifungal activity and cytotoxic effect of essential oils and extracts of medicinal and aromatic plants against Candida krusei and Aspergillus fumigatus, Braz. J. Pharm., 20(5), 734-741 (2010).
E.E. Nash, B.M. Peters, P.I. Fidel, M.C. Noverr, Morphology-independent virulence of Candida species during polymicrobial intra-abdominal infections with Staphylococcus aureus, Infect. Immun., 84(1), 90–98 (2015).
L.W.E. Chan, Y.Z. Yee, I. Raja, Y.K.J Yap, Synergistic effect of non-steroidal anti-inflammatory drugs (NSAIDs) on antibacterial activity of cefuroxime and chlotamphenicol against methicillin-resistant Staphylococcus aureus, J. Glob. Antimicrob. Resist., 10, 70-74 (2017).
C. Pina-Vaz, F. Sansonetty, G.A. Rodrigues, J. Martinez-de-Oliveira, F.A. Fonseca, P. Mardh, Antifungal activity of ibuprofen alone and in combination with fluconazole against Candida species, J. Med. Microbiol., 49(9), 831-840 (2000).
T.P. Venturini, L. Rossato, T.B. Spader, G.R. Tronco-Alves, M.I. Azevedo, C.B. Weiler, et al., In vitro synergisms obtained by amphotericin B and voriconazole associated with non-antifungal agents against Fusarium spp, Diagn. Microbiol. Infect. Dis., 71(2), 126-130 (2011).
L. Li-Juan, C. Wei, X. Hui, W. Zhe, L. Ruo-Yu, L. Wei, Antifungal activity of ibuprofen against Aspergillus species and its interaction with common antifungal drugs, Chinese J. Mycol., 123, 19 (2010).
K. Lohner, Antimicrobial mechanisms: a sponge against fungal infections, Nat. Chem. Biol., 10(6), 411-412. (2014).
K.H. Greenblatt, J. D. Greenblatt. Liver injury associated with ketoconazole: Review of the published evidence. J Clin Pharmacol, 54, 12, (2014).
C. Ceresa, M. Rinaldi, L. Fracchia, Synergistic activity of antifungal drugs and lipopeptide AC7 against Candida albicans biofilm on silicone, AIMS Bioengineering, 4(2), 318-334 (2017).
Como Citar
APA
ACM
ACS
ABNT
Chicago
Harvard
IEEE
MLA
Turabian
Vancouver
Baixar Citação
CrossRef Cited-by
1. Ksenia V. Drozd, Denis E. Boycov, Alex N. Manin, Andrei V. Churakov, German L. Perlovich. (2023). Two Novel Drug–Drug Cocrystals of Antifungal Clotrimazole with Nonsteroidal Anti-Inflammatory Drugs. Crystal Growth & Design, 23(9), p.6597. https://doi.org/10.1021/acs.cgd.3c00520.
Dimensions
PlumX
Acessos à página de resumo
Downloads
Licença
Copyright (c) 2020 Revista Colombiana de Ciencias Químico-Farmacéuticas
![Creative Commons License](http://i.creativecommons.org/l/by/4.0/88x31.png)
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
El Departamento de Farmacia de la Facultad de Ciencias de la Universidad Nacional de Colombia autoriza la fotocopia de artículos y textos para fines de uso académico o interno de las instituciones citando la fuente. Las ideas emitidas por los autores son responsabilidad expresa de estos y no de la revista.
Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons de Atribución 4.0 aprobada en Colombia. Consulte la normativa en: http://co.creativecommons.org/?page_id=13